Romosozumab (Evenity) is superior to denosumab (Prolia) in growing bone mineral density (BMD) in sufferers with glucocorticoid-induced osteoporosis (GIOP).
Romosozumab is a US Meals and Drug Administration-approved humanized monoclonal antibody used to deal with osteoporosis in postmenopausal girls with a excessive danger for facture.
The research included 70 adults with GIOP with a high-risk for osteoporotic fracture who acquired a ≥5 mg/day prednisolone dose for no less than 12 months previous to the research.
Sufferers had been randomly assigned to obtain romosozumab subcutaneously (210 mg) each month for 12 doses or denosumab subcutaneously (60 mg) each 6 months for 2 doses.
The first endpoint was the distinction in BMD on the lumber backbone from baseline to 1 12 months.
Sufferers within the romosozumab group had a considerably better enhance in backbone BMD (+7.3%) after 12 months, in contrast with these within the denosumab group (+2.3%).
Each teams had an analogous enhance in hip BMD at 1 12 months, whereas femoral neck BMD didn’t considerably enhance in both group in the course of the research interval.
The romosozumab group had a decrease drop in serum C-terminal telopeptide of kind I collagen (CTX) however confirmed a rise in procollagen kind 1 N propeptide (P1NP), in contrast with the denosumab group.
Sufferers within the romosozumab extra regularly reported injection web site ache, erythema, and swelling.
“Romosozumab could provide a brand new therapy choice in GIOP in high-risk sufferers,” write the authors.
Chi-Chiu Mok, MD, Tuen Mun Hospital, Hong Kong, led the analysis and offered abstract OP0246 on June 2 on the European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Assembly.
The trial’s small pattern measurement may restrict the interpretation of the outcomes.
The research was funded by a small grant from the Well being and Medical Analysis Fund of the Well being Bureau of the Authorities of Hong Kong.
Lead Picture: iStock/Getty Pictures
Medscape Medical Information © 2023 WebMD, LLC
Ship feedback and information tricks to [email protected].
Cite this: Romosozumab Tops Denosumab in Elevating Backbone BMD in Sufferers With GIOP – Medscape – Jun 12, 2023.